The NADPH Oxidase 4 pipeline drugs market research report outlays comprehensive information on the NADPH Oxidase 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the NADPH Oxidase 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Respiratory, Metabolic Disorders, and Genito Urinary System which include the indications Acute Ischemic Stroke, Ischemia Reperfusion Injury, Idiopathic Pulmonary Fibrosis, Type 2 Diabetes, Diabetic Complications, and Kidney Disease (Nephropathy). It also reviews key players involved in NADPH Oxidase 4 targeted therapeutics development with respective active and dormant or discontinued products.
The NADPH Oxidase 4 pipeline targets constitutes close to eight molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical, and Discovery stages are 1, 1, 4, and 1 respectively.
NADPH Oxidase 4 overview
NADPH oxidase 4 is an enzyme belonging to NOX family of NADPH oxidases. NADPH Oxidase 4 is localized to non-phagocytic cells where it acts as an oxygen sensor and catalyzes the reduction of molecular oxygen to various reactive oxygen species. So formed ROS have been implicated in numerous biological functions including signal transduction, cell differentiation and tumor cell growth.
For a complete picture of NADPH Oxidase 4’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
